Amneal Introduces Bimatoprost Ophthalmic Solution To Treat Glaucoma And Ocular Hypertension

Amneal Pharmaceuticals has announced the launch of bimatoprost ophthalmic solution 0.01% in multiple pack sizes (2.5 mL, 5 mL, and 7.5 mL). This product is the generic equivalent of LUMIGAN 0.01%, originally developed by Allergan, which is now part of AbbVie.

Bimatoprost ophthalmic solution is a prostaglandin analog used to lower elevated intraocular pressure in patients diagnosed with open-angle glaucoma or ocular hypertension. By improving fluid outflow from the eye, it helps reduce the risk of vision loss associated with these conditions.

“We are pleased to bring another key ophthalmic therapy to our Affordable Medicines portfolio,” said Dr. Srinivas Kone, Senior Vice President, Chief Scientific Officer – Affordable Medicines. “As glaucoma prevalence continues to rise, particularly among the aging population, expanding access to effective treatments like bimatoprost is critical. This launch builds on our strong cadence of complex product introductions and represents an important growth driver for our Affordable Medicines segment.”

The most commonly reported side effect of this medication is conjunctival hyperemia, which typically presents as redness in the eye. Patients are advised to refer to the prescribing information for a complete understanding of potential adverse reactions and proper usage guidelines.

According to IQVIA data, the U.S. market for bimatoprost ophthalmic solution 0.01% recorded annual sales of approximately $719 million for the 12 months ending February 2026, indicating a strong commercial opportunity for Amneal in this therapeutic segment.

Also Read

Amneal Pharmaceuticals Donates $2 Million To Support Parkinson’s Patients And Expand Access To Essential Treatments